Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Indo US Bio-Tech
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 15.50 | 18.11 | 19.14 | 15.81 | 22.11 | 15.77 | 24.72 | 22.17 | 23.56 | 33.38 | 30.77 | 30.85 | 22.80 |
| Expenses + | 13.44 | 15.02 | 16.15 | 13.21 | 17.88 | 14.79 | 21.03 | 17.05 | 18.02 | 28.80 | 25.30 | 26.69 | 18.65 |
| Operating Profit | 2.06 | 3.09 | 2.99 | 2.60 | 4.23 | 0.98 | 3.69 | 5.12 | 5.54 | 4.58 | 5.47 | 4.16 | 4.15 |
| OPM % | 13.29% | 17.06% | 15.62% | 16.45% | 19.13% | 6.21% | 14.93% | 23.09% | 23.51% | 13.72% | 17.78% | 13.48% | 18.20% |
| Other Income + | 0.00 | 0.02 | 0.03 | 0.00 | 0.08 | 0.21 | 0.03 | 0.02 | 0.02 | 0.12 | 0.00 | 0.03 | 0.01 |
| Interest | 0.41 | 0.27 | 0.37 | 0.41 | 0.37 | 0.36 | 0.33 | 0.52 | 0.38 | 0.26 | 0.45 | 0.42 | 0.77 |
| Depreciation | 0.29 | 0.21 | 0.20 | 0.21 | 0.19 | 0.20 | 0.20 | 0.18 | 0.16 | 0.56 | 0.20 | 0.21 | 0.22 |
| Profit before tax | 1.36 | 2.63 | 2.45 | 1.98 | 3.75 | 0.63 | 3.19 | 4.44 | 5.02 | 3.88 | 4.82 | 3.56 | 3.17 |
| Tax % | -1.47% | -5.32% | 3.27% | 15.66% | 1.87% | 17.46% | 0.63% | 2.03% | -0.80% | 4.90% | 2.49% | 3.09% | 5.36% |
| Net Profit + | 1.37 | 2.77 | 2.37 | 1.67 | 3.68 | 0.52 | 3.17 | 4.36 | 5.05 | 3.68 | 4.70 | 3.45 | 3.00 |
| EPS in Rs | 0.68 | 1.38 | 1.18 | 0.83 | 1.84 | 0.26 | 1.58 | 2.17 | 2.52 | 1.84 | 2.34 | 1.72 | 1.50 |
Financials of Indo US Bio-Tech
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 15 | 20 | 19 | 24 | 29 | 35 | 40 | 39 | 49 | 61 | 73 | 104 | 118 |
| Expenses + | 14 | 19 | 19 | 23 | 27 | 32 | 36 | 34 | 42 | 51 | 62 | 85 | 99 |
| Operating Profit | 0 | 1 | 0 | 1 | 3 | 3 | 4 | 6 | 7 | 9 | 11 | 19 | 18 |
| OPM % | 3% | 3% | 3% | 5% | 9% | 10% | 10% | 14% | 14% | 15% | 15% | 18% | 16% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 4 | 5 | 7 | 9 | 17 | 15 |
| Tax % | -136% | -92% | -50% | 25% | 29% | 26% | 12% | -23% | 5% | 2% | 6% | 2% | |
| Net Profit + | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 5 | 5 | 7 | 8 | 16 | 15 |
| EPS in Rs | 0.72 | 1.11 | 0.80 | 0.89 | 1.41 | 1.44 | 1.74 | 3.52 | 2.86 | 3.60 | 4.11 | 8.11 | 7.40 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Indo US Bio-Tech
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 3 | 5 | 6 | 6 | 9 | 10 | 20 | 20 | 20 |
| Reserves | 1 | 1 | 2 | 2 | 2 | 9 | 10 | 15 | 30 | 44 | 43 | 58 | 67 |
| Borrowings + | 2 | 2 | 5 | 5 | 7 | 6 | 9 | 11 | 12 | 12 | 14 | 15 | 28 |
| Other Liabilities + | 2 | 3 | 6 | 4 | 6 | 4 | 10 | 11 | 4 | 3 | 7 | 4 | 3 |
| Total Liabilities | 6 | 8 | 14 | 13 | 17 | 24 | 35 | 44 | 56 | 69 | 84 | 98 | 117 |
| Fixed Assets + | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 6 | 7 | 7 | 10 | 10 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 4 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 5 | 7 | 13 | 11 | 16 | 21 | 32 | 39 | 48 | 61 | 74 | 88 | 108 |
| Total Assets | 6 | 8 | 14 | 13 | 17 | 24 | 35 | 44 | 56 | 69 | 84 | 98 | 117 |
Financials of Indo US Bio-Tech
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -1 | -3 | -1 | 0 | 3 | 1 | 2 | 1 | |||
| Cash from Investing Activity + | -0 | 0 | -3 | -1 | -2 | -5 | -7 | -3 | -1 | |||
| Cash from Financing Activity + | 0 | 1 | 6 | 2 | 1 | 2 | 6 | 1 | -1 | |||
| Net Cash Flow | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 1 | -1 | |||
| Free Cash Flow | -0 | -1 | -4 | -1 | -2 | -1 | -1 | -0 | 1 | |||
| CFO/OP | 11% | -16% | -92% | -20% | 6% | 47% | 9% | 23% | 9% |
Financials of Indo US Bio-Tech
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 25 | 107 | 76 | 112 | 94 | 193 | 229 | 152 | 148 | 95 | 53 |
| Inventory Days | 64 | 91 | 118 | 92 | 98 | 176 | 751 | |||||
| Days Payable | 51 | 57 | 115 | 64 | 71 | 34 | 667 | |||||
| Cash Conversion Cycle | 62 | 59 | 110 | 104 | 138 | 236 | 276 | 229 | 152 | 148 | 95 | 53 |
| Working Capital Days | 75 | 66 | 33 | 34 | 59 | 129 | 137 | 186 | 257 | 285 | 266 | 247 |
| ROCE % | 9% | 14% | 7% | 14% | 28% | 20% | 17% | 18% | 16% | 15% | 14% | 21% |
If you can provide a valid transcript or document, I will be happy to assist with your query. Key concall takeaways from Dwarikesh Sugar Industries Ltd's Q4…
The provided PDF page contains a "500 . Key concall takeaways from Dwarikesh Sugar Industries Ltd's Q3 FY23 earnings call — and how it ranks against sector…
Management is optimistic about sustaining EBITDA margins (12-14%) with profitable business mix. Key concall takeaways from Chamanlal Setia's Q1 FY27 earnings…
100 crores revenue in vegetables within 3 to 5 years. Key concall takeaways from Kaveri Seed Company Ltd's Q1 FY27 earnings call — and how it ranks against…